These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1374 related articles for article (PubMed ID: 19506361)

  • 21. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of inherited von Willebrand disease in 2007.
    Federici AB; Mannucci PM
    Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.
    Favaloro EJ; Thom J; Patterson D; Just S; Baccala M; Dixon T; Meiring M; Koutts J; Rowell J; Baker R
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):475-83. PubMed ID: 19584715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory diagnosis of congenital von Willebrand disease.
    Budde U; Drewke E; Mainusch K; Schneppenheim R
    Semin Thromb Hemost; 2002 Apr; 28(2):173-90. PubMed ID: 11992241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rethinking the diagnosis of von Willebrand disease.
    Favaloro EJ
    Thromb Res; 2011 Jan; 127 Suppl 2():S17-21. PubMed ID: 21193108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor.
    Hilbert L; Jenkins PV; Gaucher C; Meriane E; Collins PW; Pasi KJ; Mazurier C
    Thromb Haemost; 2000 Aug; 84(2):188-94. PubMed ID: 10959688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
    Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
    Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function.
    Meyer D; Fressinaud E; Hilbert L; Ribba AS; Lavergne JM; Mazurier C
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):349-64. PubMed ID: 11686104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
    Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases].
    César JM; Avello AG; Vecino A; Cerveró C; Laraña JG; Fuertes IF; Villarrubia J; López J; de Oteyza JP; Velasco JL; Cantalapiedra A; Herrera P; Herrero S; Navarro JL
    Med Clin (Barc); 1998 Nov; 111(16):601-3. PubMed ID: 9881332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M; Kimura A; Chiba Y; Yoshida Y
    Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.